| Autor: |
Hasanbegović, Berisa, Bašić, Hiba, Obralić, Nermina, Bešlija, Semir |
| Předmět: |
|
| Zdroj: |
Folia Medica Facultatis Medicinae Universitatis Saraeviensis; 2012, Vol. 47 Issue 1, p79-88, 10p |
| Abstrakt: |
Goal: The primary goal of our study is to evaluate the influence of adding taxane to antracycline in adjuvant chemotherapy treatment of early breast cancer on disease free survival (DFS). The secondary goal is to compare the toxicity profile of chemotherapy (CT) regimens in the study and control groups. Materials and methods: We conducted retrospective, epidemiological, observational clinical research in patients with pathologicaly verified early breast cancer (EBC), treated between 2005 and 2007 with adjuvant CT, antracycline- based or antrycycline plus taxane. We analyzed the DFS and adverse events (AE) of CT regimens. Results: 61% of all patients did not progress after adjuvant therapy, including 69% of those in the study group (n=29) and 57% of those in the control group (n=53). The difference in DFS between the study (A) and control (B) groups is not significant (41.04 vs. 40.83 months, respectively). CT toxicity in both groups was tolerable, with no serious AE. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
